ArticleArthritis research & therapy2017

The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs.

Soo-Kyung Cho et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.